Options
ABUS options chain
Explore expirations, strikes, liquidity, live quotes and Greeks in the context of the same company overview.
Options Chain SnapshotA bounded snapshot of up to 200 active contracts in the displayed expiration and strike window. Close and open interest are reference fields, not live quotes.
Up to 200 active ABUS contracts expiring in the next 7–45 days, with strikes within ±25% of the current price.
| Expiration | Days to expiry | Shown contracts |
|---|---|---|
| 2026-12-18 | 26 | 8 |
| Type | Strike | Expiry | Open interest | Close |
|---|---|---|---|---|
| Call | $3.50 | 2026-12-18 | — | — |
| Call | $4.00 | 2026-12-18 | 3 | $0.27 |
| Call | $4.50 | 2026-12-18 | 1 | $0.05 |
| Call | $5.00 | 2026-12-18 | 735 | $0.10 |
| Put | $3.50 | 2026-12-18 | — | — |
| Put | $4.00 | 2026-12-18 | 2 | $0.55 |
| Put | $4.50 | 2026-12-18 | — | — |
| Put | $5.00 | 2026-12-18 | 25 | $1.00 |
- Source
- US listed-options contracts feed
- Observed
- Cadence
- Five-minute cached contract snapshot
- Status
- fresh
Live Quotes & GreeksThis analysis is included with a paid membership. Public prices, charts and source-attributed news remain available without a subscription. Membership does not guarantee an investment outcome.
Options Ideas & Decision IntelligenceThis analysis is included with a paid membership. Public prices, charts and source-attributed news remain available without a subscription. Membership does not guarantee an investment outcome.
Asset BackgroundSource-supported background about this asset. The sources and review status are listed with the reference.
ABUS options refer to Arbutus Biopharma Corp as their underlying. Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.
AI-selected reference, checked against source evidence · Evidence observed
Frequently Asked QuestionsSource-linked answers to common questions about this asset. Check the evidence observation date and whether the reference was reviewed by a person.
- What business does Arbutus Biopharma Corp operate?
- Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.
- How do ABUS options relate to the underlying company?
- The published options record identifies ABUS as an underlying symbol. Options contracts reference that underlying; expiration, strike and option type define each separate contract.
What to WatchAI-assisted topics for further research about this asset. These are educational prompts, not trading signals or recommendations.
- Business activities described in the company reference
- Original company disclosures and industry classification